Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC001592 | Panoply™ Human BTNL8 Knockdown Stable Cell Line | Inquiry |
| CSC-SC001592 | Panoply™ Human BTNL8 Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD01966Z | Human BTNL8 adenoviral particles | Inquiry |
| LV06430L | human BTNL8 (NM_001159707) lentivirus particles | Inquiry |
| LV06431L | human BTNL8 (NM_024850) lentivirus particles | Inquiry |
| LV06432L | human BTNL8 (NM_001159710) lentivirus particles | Inquiry |
| LV06433L | human BTNL8 (NM_001040462) lentivirus particles | Inquiry |
| LV06434L | human BTNL8 (NM_001159708) lentivirus particles | Inquiry |
| LV06435L | human BTNL8 (NM_001159709) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHG108037 | shRNA set against Rat Btnl8(NM_212489.1) | Inquiry |
| SHH248406 | shRNA set against Human BTNL8 (NM_024850.2) | Inquiry |
| SHH248410 | shRNA set against Rat BTNL8 (NM_212489.1) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCR035776 | Human BTNL8 ORF clone (NM_001159709.1) | Inquiry |
| CDFH001984 | Human BTNL8 cDNA Clone(NM_001159708.1) | Inquiry |
| CDFH001985 | Human BTNL8 cDNA Clone(NM_001159710.1) | Inquiry |
| CDFH001986 | Human BTNL8 cDNA Clone(NM_001159707.1) | Inquiry |
| CDFH001987 | Human BTNL8 cDNA Clone(NM_001159709.1) | Inquiry |
| CDFR015373 | Rat Btnl8 cDNA Clone(NM_212489.1) | Inquiry |
| MiUTR1R-00628 | BTNL8 miRNA 3'UTR clone | Inquiry |
| MiUTR4H-TG00873 | BTNL8 miRNA 3'UTR clone | Inquiry |
| CDCR035772 | Human BTNL8 ORF clone (NM_001159707.1) | Inquiry |
| CDCR035774 | Human BTNL8 ORF clone (NM_001159708.1) | Inquiry |
| CDCR035778 | Human BTNL8 ORF clone (NM_001159710.1) | Inquiry |
| CDCR382149 | Rat Btnl8 ORF Clone(NM_212489.1) | Inquiry |
| CDCS407052 | Human BTNL8 ORF Clone (BC119696) | Inquiry |